Metagenomi is a technology company.
Metagenomi has raised $281.0M across 3 funding rounds.
Metagenomi has raised $281.0M in total across 3 funding rounds.
Metagenomi has raised $281.0M in total across 3 funding rounds.
Metagenomi's investors include 5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, Humboldt Fund, Nextech Invest, OrbiMed, RA Capital, Tencent Holdings, Jeremy Yap, Tribe Capital.
Metagenomi is a precision genetic medicines company developing curative therapeutics through an AI-driven metagenomics platform that discovers novel genome editing tools from uncultured microbes in natural environments.[1][2][4] It builds a comprehensive toolbox of editing systems—including programmable nucleases, base editors, prime editors, and compact CAST systems for large gene integration—to target any genetic mutation anywhere in the human genome, addressing limitations of first-generation CRISPR-Cas9 tools.[1][2][5] Serving patients with complex genetic diseases like Wilson's disease and cystic fibrosis, Metagenomi solves the problem of imprecise, inefficient, or delivery-challenged gene editing by offering ultra-small, highly specific, low-immunogenic systems that enable site-specific deletions, integrations, and corrections.[1][4] The company has demonstrated breakthroughs, such as integrating large therapeutic genes into human cells using a single mRNA-based CAST system, and was named one of Fast Company's World's Most Innovative Companies for its library of over 20,000 editing systems.[1][2]
Metagenomi was founded by pioneers in metagenomics, including Brian C. Thomas, PhD, its co-founder and former CEO, who led the company's early vision to harness genetic material from uncultivated organisms.[2][5][6] The idea emerged from recognizing that traditional lab-cultured microbes represent only a fraction of Earth's microbial diversity; instead, metagenomics allows recovery and sequencing of genomes directly from diverse natural environments like soils and extreme climates, unlocking four billion years of evolution for novel editing tools.[1][4][5] Early traction came from building an industry-leading database through proprietary sampling expeditions, AI-enabled screening, and high-throughput testing, resulting in libraries of millions of nucleases, deaminases, reverse transcriptases, and over 1,000 CAST systems—far beyond standard CRISPR discoveries.[2][5] Pivotal moments include publishing data on programmable large gene integration with compact Cas12k CAST and earning innovation accolades, solidifying its disruptor status in gene editing.[1][2]
Metagenomi rides the wave of next-generation gene editing, expanding beyond CRISPR-Cas9's limitations to enable precise, large-scale genomic "resculpting" for curative therapies in genetic diseases.[1][2][4] Timing is ideal amid surging demand for in vivo editing tools that overcome delivery hurdles and off-target risks, fueled by market forces like advancing AI in biotech, growing metagenomics datasets, and regulatory momentum for gene therapies (e.g., FDA approvals for similar modalities).[1][5] It influences the ecosystem by pioneering compact CAST systems for large gene insertion—previously unfeasible—and sharing a massive, proprietary library that could accelerate industry-wide innovation, positioning it as a key enabler for treating previously intractable mutations.[1][2]
Metagenomi is poised to advance its pipeline with clinical-stage programs leveraging CAST and other tools for diseases like cystic fibrosis, while expanding its metagenomics database for even more potent editors.[1][4] Trends like AI-biotech convergence, cheaper sequencing, and in vivo delivery improvements will amplify its edge, potentially yielding first-in-class approvals and partnerships.[2][5] Its influence may evolve from tool discoverer to full-stack genetic medicine leader, resculpting genomes to cure the uncurable—transforming a technology company into a cornerstone of precision medicine.[1][4]
Metagenomi has raised $281.0M across 3 funding rounds. Most recently, it raised $180.0M Series B in January 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2022 | $180.0M Series B | 5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, Humboldt Fund, Nextech Invest, OrbiMed, RA Capital, Tencent Holdings, Jeremy Yap | |
| Nov 1, 2020 | $75.0M Series A | 5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, Humboldt Fund, Nextech Invest, OrbiMed, RA Capital | |
| Aug 1, 2019 | $26.0M Series A | Humboldt Fund, Tribe Capital, Justin Mateen, Omar El-Ayat, Tom Williams |